Regado shares pop as drug wins fast-track status

Regado Biosciences ($RGDO) earned a pop in its stock price this morning after it put out word that the FDA has granted fast-track status to its anticoagulant REG1. The Basking Ridge, NJ-based biotech's share price is up more than 20% on Monday morning. "We continue to believe that REG1 has the potential to become a new standard of care for anticoagulation in interventional cardiology," noted CEO David Mazzo in a statement. Release

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.